Physicians' Academy for Cardiovascular Education

Rivaroxaban plus aspirin, lowers CV and major adverse limb events, but increases bleeding in patients with stable CAD and PAD

Literature -

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Connolly SJ, Eikelboom JW, Bosch J, et al. The Lancet 2018;391:205-218

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Anand SS, Bosch J, Eikelboom JW, et al. The Lancet 2018;391:219-229

Main results

Patients with stable CAD (Connolly et al.)

Patients with PAD (Anand et al.)

Conclusion

Addition of low-dose rivaroxaban to aspirin reduces major CV events and limb events in patients with stable CAD or PAD. However, there is also an increased risk for bleeding, although few critical or fatal bleedings occurred after dual treatment. Therefore, low-dose rivaroxaban in combination with aspirin can be of clinical benefit in a broad group of patients with CAD and PAD.

References

Show references

Find Connolly et al online at The Lancet 2018 Find Anand et al online at The Lancet 2018

Share this page with your colleagues and friends: